1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)-
![1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)- Structure](CAS/20210305/GIF/1414943-94-4.gif)
- CAS No.
- 1414943-94-4
- Chemical Name:
- 1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)-
- Synonyms
- (+)-(3-((4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl)amino)benzyl)(imino)(methyl)-l6-sulfanone
- CBNumber:
- CB98673544
- Molecular Formula:
- C18H18FN5O2S
- Molecular Weight:
- 387.43
- MDL Number:
- MOL File:
- 1414943-94-4.mol
- MSDS File:
- SDS
- TDS File:
- TDS
1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)- Properties
| Boiling point | 589.9±60.0 °C(Predicted) |
|---|---|
| Density | 1.36±0.1 g/cm3(Predicted) |
| FDA UNII | 63Q7F59W0V |
1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)- price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 44337 | Atuveciclib ≥95% | 1414943-94-4 | 5mg | $274 | 2026-04-30 | Buy |
| Cayman Chemical | 44337 | Atuveciclib ≥95% | 1414943-94-4 | 10mg | $493 | 2026-04-30 | Buy |
| Cayman Chemical | 44337 | Atuveciclib ≥95% | 1414943-94-4 | 25mg | $822 | 2026-04-30 | Buy |
| Cayman Chemical | 44337 | Atuveciclib ≥95% | 1414943-94-4 | 50mg | $1370 | 2026-04-30 | Buy |
1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)- Chemical Properties, Uses, Production
Uses
(+)-Atuveciclib is the isomer of Atuveciclib (Racemate) (HY-12871). Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective，oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
References
[1] Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3022.
[2] Scholz A, et al. BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr DDT02-02. doi:10.1158/1538-7445.AM2015-DDT02-02
1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)- Preparation Products And Raw materials
Raw materials
Preparation Products
1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-, (+)- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Rechem science Co., Ltd. | 021-31433387 15618786686 | sales@rechemscience.com | China | 2969 | 58 |
| cjbscvictory | 13348960310 13348960310 | 3003867561@qq.com | China | 10233 | 58 |
| Nantong QuanYi Biotechnology Co., Ltd | 0513-66337626 18051384581 | sales@chemhifuture.com | China | 5985 | 58 |
| Aikon International Limited | 025-58859352 18651614124 | 2881516338@qq.com | China | 9968 | 58 |
| Supplier | Advantage |
|---|---|
| Shanghai Rechem science Co., Ltd. | 58 |
| cjbscvictory | 58 |
| Nantong QuanYi Biotechnology Co., Ltd | 58 |
| Aikon International Limited | 58 |
